Abiopharma

(70% Positive) PALVELLA THERAPEUTICS, INC. (PIRS) Announces Enrollment Update for Data Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

Amphastar Announces FDA Approval for Teriparatide Injection

Greenwich LifeSciences Announces Preliminary Analysis Showing 80% Recurrence Rate Reduction in the Open Label Arm of FLAMINGO-01

Change - Announcement of Cessation: Announcement of Cessation

Change - Announcement of Cessation: Announcement of Cessation

Change - Announcement of Cessation: Announcement of Cessation

Labeling changes approved for INGENUS PHARMS LLC. Active ingredient: CABERGOLINE. Decision date: 12/11/2025

Labeling changes approved for ALKEM LABS LTD. Active ingredient: OXYCODONE HYDROCHLORIDE. Decision date: 12/12/2025

Final approval of ANDA #ANDA #219161 for OMEPRAZOLE; SODIUM BICARBONATE. Decision date: 12/10/2025

Final approval of ANDA #ANDA #218473 for BUPRENORPHINE HYDROCHLORIDE. Decision date: 12/10/2025

Labeling changes approved for SHREE HARI INTL. Active ingredient: AMANTADINE HYDROCHLORIDE. Decision date: 12/05/2025

General Announcement: CHANGES IN SUBSTANTIAL SHAREHOLDERS INTEREST PURSUANT TO SECTION 138 OF THE COMPANIES ACT, 2016

Reviva Pharmaceuticals Holdings Inc. (RVPHW) was removed from the list of traded instruments on NASDAQ exchange

NASDAQ symbol attribute type Financial_Status was changed. Previous value: N. New value: Reviva Pharmaceuticals Holdings, Inc. - Warrants.

NASDAQ symbol attribute type Test_mode was changed. Previous value: N. New value: Reviva Pharmaceuticals Holdings, Inc. - Warrants.